Topiramate: Safety and Efficacy of its Use in the Prevention and Treatment of Migraine

被引：25

作者：

Minton, Ginger C. ^{[1
]}

Miller, April D. ^{[2
]}

Bookstaver, P. Brandon ^{[2
]}

Love, Bryan L. ^{[2
]}

机构：

[1] Univ South Carolina Campus, South Carolina Coll Pharm, Columbia, SC USA

[2] Univ South Carolina Campus, Dept Clin Pharm & Outcomes Sci, South Carolina Coll Pharm, Columbia, SC 29208 USA

来源：

JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE | 2011年 / 3卷

关键词：

topiramate; migraine; prophylaxis;

D O I：

10.4137/JCNSD.S4365

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Migraine headaches are typically episodic in nature and may affect nearly 10% of the population. In addition to treatment, prevention of subsequent episodes or progression to a chronic migraine state is an important therapeutic area. Topiramate is a centrally acting medication approved for both the prevention of seizures and migraine headache. At this time, the exact mechanism of how topiramate assists in migraine prevention is unknown. Several large randomized, controlled trials have aided in establishing topiramate's role in migraine prevention. Despite a favorable pharmacokinetic and adverse effect profile established in clinical trials, several additional studies, case reports and toxicology reports have demonstrated topiramate as a cause of cognitive and behavioural changes. The use of topiramate in migraine prevention can improve a patient's quality of life and is a cost-effective option for migraine prevention.

引用

页码：155 / 168

页数：14

共 52 条

[1] Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials [J].

Adelman, James ;

Freitag, Fred G. ;

Lainez, Miguel ;

Shi, Yingqi ;

Ascher, Steven ;

Mao, Lian ;

Greenberg, Steven ;

Hulihan, Joseph .

PAIN MEDICINE, 2008, 9 (02) :175-185

[2]

[Anonymous], 2008, TOP TOP PACK INS

[3] A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis [J].

Ashtari, F. ;

Shaygannejad, V. ;

Akbari, M. .

ACTA NEUROLOGICA SCANDINAVICA, 2008, 118 (05) :301-305

[4] Pharmacokinetic interactions of topiramate [J].

Bialer, M ;

Doose, DR ;

Murthy, B ;

Curtin, C ;

Wang, SS ;

Twyman, RE ;

Schwabe, S .

CLINICAL PHARMACOKINETICS, 2004, 43 (12) :763-780

[5] Modifiable risk factors for migraine progression (or for chronic daily headaches) - Clinical lessons [J].

Bigal, Marcelo E. ;

Lipton, Richard B. .

HEADACHE, 2006, 46 :S144-S146

[6] Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004 [J].

Brainin, M ;

Barnes, M ;

Baron, JC ;

Gilhus, NE ;

Hughes, R ;

Selmaj, K ;

Waldemar, G .

EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (09) :577-581

[7] Assessing the ability of topiramate to improve the daily activities of patients with migraine [J].

Brandes, Jan Lewis ;

Kudrow, David B. ;

Rothrock, John F. ;

Rupnow, Marcia F. T. ;

Fairclough, Diane L. ;

Greenberg, Steven J. .

MAYO CLINIC PROCEEDINGS, 2006, 81 (10) :1311-1319

[8] Topiramate for migraine prevention - A randomized controlled trial [J].

Brandes, JL ;

Saper, JR ;

Diamond, M ;

Couch, JR ;

Lewis, DW ;

Schmitt, J ;

Neto, W ;

Schwabe, S ;

Jacobs, D .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (08) :965-973

[9] Cost-effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment [J].

Brown, JS ;

Papadopoulos, G ;

Neumann, PJ ;

Friedman, M ;

Miller, JD ;

Menzin, J .

HEADACHE, 2005, 45 (08) :1012-1022

[10] Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study [J].

Diener, H-C ;

Bussone, G. ;

Van Oene, J. C. ;

Lahaye, M. ;

Schwalen, S. ;

Goadsby, P. J. .

CEPHALALGIA, 2007, 27 (07) :814-823

← 1 2 3 4 5 6 →